doi: 10.1371/journal.ppat.1002473. EV71, and perhaps for other enteroviruses, as well. IMPORTANCE Enterovirus 71 (EV71) infection may lead to severe hand, foot, and mouth disease, with significant morbidity and mortality. Knowledge regarding EV71 particle assembly remains limited. Here, we report the generation and characterization of a novel EV71 virus-like particle that lacks the VP4 capsid subunit protein. This particle, termed VLPVP4, structurally mimics the 80S empty capsid, which is the end stage of EV71 uncoating. We further show that VLPVP4 exhibits desirable immunogenicity and protective efficacy in proof-of-concept studies. In addition, the inhibitory mechanisms of the VLPVP4-induced antibodies are unraveled at both the E7820 cellular and molecular levels. Our work provides the first evidence of picornaviral particle assembly in the complete absence of VP4 and identifies VLPVP4 as an improved EV71 vaccine candidate with desirable traits. These findings not only enhance our understanding of particle assembly and uncoating of picornaviruses, but also provide important information for structure-guided vaccine design for EV71 E7820 and other enteroviruses. KEYWORDS: cryo-EM, enterovirus 71, structure, uncoating, vaccine, virus-like particle INTRODUCTION Enterovirus 71 (EV71), a member of the genus of the family 0.05; ***, < 0.001. Our cryo-EM reconstruction showed that the VP1 N terminus of VLPVP4 is externalized (Fig. 4D to ?toF).F). To verify this structural feature, we generated a polyclonal antibody specific for the first 75 amino acids of VP1 and used the antibody to examine the exposure of E7820 N-terminal VP1. As expected, the antibody was capable of recognizing the mixed 135S A particle and 80S empty capsid (generated by heating mature virions in hypotonic buffer, as described previously [10]), whereas it did not recognize the mature virion, for which the N terminus of VP1 was at the inner surface (3) (Fig. 5C), thus validating the use of the antibody for detection of the externalized VP1 N terminus. We then compared the reactivities of VLPVP4 and VLPfull with the N-terminal VP1-specific antibody. As shown in Fig. 5D, VLPfull, whose VP1 N terminus is at the inner E7820 face (19), did not react with the antibody; in contrast, VLPVP4 exhibited strong reactivity, indicating the externalization of the VP1 N terminus of VLPVP4. We also determined the reactivity of VLPVP4 with a monoclonal antibody, D5, which recognizes the exposed VP1 GH loop (28), an immunodominant neutralization epitope (20). As shown E7820 in Fig. 5E, both VLPVP4 and VLPfull reacted strongly with D5, indicating that VLPVP4 retains the antigenic property of the VP1 GH loop. The antibody profile induced by immunization with VLPVP4 was different from that with VLPfull. The absence of VP4 and externalization of the VP1 N terminus may provide VLPVP4 with immunogenic properties distinct from those of VLPfull. To verify this hypothesis, we immunized three groups of mice with VLPVP4, VLPfull, and phosphate-buffered saline (PBS) (as a control) and compared the resulting antisera for reactivity with recombinant VP4 and VP1-N75 (comprising N-terminal residues 1 to 75 of VP1) proteins. As shown in Fig. 6A and ?andB,B, the control anti-PBS serum did not react with either VP4 or VP1-N75, and the anti-VLPVP4 serum did not react significantly with VP4 but did react strongly with VP1-N75; on the other hand, anti-VLPfull reacted significantly with VP4 but not with VP1-N75. We also compared the three groups of antisera for reactivity with the SP70 peptide (residues 208 to 222 of VP1, representing the VP1 GH loop). The SP70-binding activities of the anti-VLPVP4 sera appeared to be comparable to those of the anti-VLPfull sera (Fig. 6C), consistent with the antigenicity result Rabbit Polyclonal to 5-HT-3A showing that the VP1 GH loop epitopes were well retained on both VLPVP4 and VLPfull (Fig. 5E). The above-mentioned data demonstrate that antibodies targeting the VP4 or VP1 N terminus were distinctly elicited by VLPVP4 and VLPfull. Open in a separate window FIG 6 Binding specificities of sera from VLP-immunized mice. (A) VP4-binding activities of individual antisera. (B) VP1-N75-binding activities of individual antisera. (C) SP70 peptide-binding activities of individual antisera. Each symbol represents an individual mouse, and the horizontal lines indicate the geometric mean values of the groups. Statistical significances were determined by one-way ANOVA using GraphPad Prism version 5. ns, 0.05; *, < 0.05; **, < 0.01; ***, < 0.001. Protective efficacy of VLPVP4. We compared the neutralization potencies of.
